Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic
stem cell composition in vivo, and whether these changes can be reversed with glucagon like
peptide 1 receptor (GLP1R)-agonism.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)